Cargando…

Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients

We investigated the prognostic significance of circulating breast cancer cells in peripheral blood detected by quantitative RT–PCR of marker genes in patients with advanced breast cancer. Blood samples from 94 breast cancer patients with metastatic disease (M1) were examined for circulating tumour c...

Descripción completa

Detalles Bibliográficos
Autores principales: Weigelt, B, Bosma, A J, Hart, A A M, Rodenhuis, S, van 't Veer, L J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376386/
https://www.ncbi.nlm.nih.gov/pubmed/12671691
http://dx.doi.org/10.1038/sj.bjc.6600868
_version_ 1782154734557200384
author Weigelt, B
Bosma, A J
Hart, A A M
Rodenhuis, S
van 't Veer, L J
author_facet Weigelt, B
Bosma, A J
Hart, A A M
Rodenhuis, S
van 't Veer, L J
author_sort Weigelt, B
collection PubMed
description We investigated the prognostic significance of circulating breast cancer cells in peripheral blood detected by quantitative RT–PCR of marker genes in patients with advanced breast cancer. Blood samples from 94 breast cancer patients with metastatic disease (M1) were examined for circulating tumour cells by studying the mRNA expression of CK19, p1B, PS2 and EGP2 by real-time PCR. Using a score function, developed for predicting circulating tumour cells by quadratic discriminant analysis (QDA), the four expression levels were combined into a single discriminant value. Tumour cells were present in 24 out of 94 (31%) of the patients. In 77% (72 out of 94) of the patients distant metastatic disease was localised in the bone. In 36% (26 out of 72) of the patients with bone metastases at the time of blood sampling, a positive QDA for the four genes was found, in contrast to only 14% (three out of 22) without bone involvement. Overall survival rates by Kaplan–Meier revealed no prognostic effect for the presence of bone metastases (P=0.93). However, patients with a positive QDA value did have a progression-free survival at 1 year of 3% and overall survival at 2 years of 17%, against 22 and 36% for patients with a negative QDA value (P=0.015 and 0.0053, respectively). Breast cancer patients with metastatic disease have a significantly worse progression-free and overall survival when circulating tumour cells can be detected in their peripheral blood.
format Text
id pubmed-2376386
institution National Center for Biotechnology Information
language English
publishDate 2003
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23763862009-09-10 Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients Weigelt, B Bosma, A J Hart, A A M Rodenhuis, S van 't Veer, L J Br J Cancer Molecular and Cellular Pathology We investigated the prognostic significance of circulating breast cancer cells in peripheral blood detected by quantitative RT–PCR of marker genes in patients with advanced breast cancer. Blood samples from 94 breast cancer patients with metastatic disease (M1) were examined for circulating tumour cells by studying the mRNA expression of CK19, p1B, PS2 and EGP2 by real-time PCR. Using a score function, developed for predicting circulating tumour cells by quadratic discriminant analysis (QDA), the four expression levels were combined into a single discriminant value. Tumour cells were present in 24 out of 94 (31%) of the patients. In 77% (72 out of 94) of the patients distant metastatic disease was localised in the bone. In 36% (26 out of 72) of the patients with bone metastases at the time of blood sampling, a positive QDA for the four genes was found, in contrast to only 14% (three out of 22) without bone involvement. Overall survival rates by Kaplan–Meier revealed no prognostic effect for the presence of bone metastases (P=0.93). However, patients with a positive QDA value did have a progression-free survival at 1 year of 3% and overall survival at 2 years of 17%, against 22 and 36% for patients with a negative QDA value (P=0.015 and 0.0053, respectively). Breast cancer patients with metastatic disease have a significantly worse progression-free and overall survival when circulating tumour cells can be detected in their peripheral blood. Nature Publishing Group 2003-04-07 2003-04-01 /pmc/articles/PMC2376386/ /pubmed/12671691 http://dx.doi.org/10.1038/sj.bjc.6600868 Text en Copyright © 2003 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Molecular and Cellular Pathology
Weigelt, B
Bosma, A J
Hart, A A M
Rodenhuis, S
van 't Veer, L J
Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients
title Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients
title_full Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients
title_fullStr Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients
title_full_unstemmed Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients
title_short Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients
title_sort marker genes for circulating tumour cells predict survival in metastasized breast cancer patients
topic Molecular and Cellular Pathology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376386/
https://www.ncbi.nlm.nih.gov/pubmed/12671691
http://dx.doi.org/10.1038/sj.bjc.6600868
work_keys_str_mv AT weigeltb markergenesforcirculatingtumourcellspredictsurvivalinmetastasizedbreastcancerpatients
AT bosmaaj markergenesforcirculatingtumourcellspredictsurvivalinmetastasizedbreastcancerpatients
AT hartaam markergenesforcirculatingtumourcellspredictsurvivalinmetastasizedbreastcancerpatients
AT rodenhuiss markergenesforcirculatingtumourcellspredictsurvivalinmetastasizedbreastcancerpatients
AT vantveerlj markergenesforcirculatingtumourcellspredictsurvivalinmetastasizedbreastcancerpatients